Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004.
The insulin-like growth factor (IGF) axis plays a role in growth and progression of prostate cancer. High circulating IGF-1 levels have been associated with an increased risk of prostate cancer. Results for IGF binding protein 3 (IGFBP-3) are inconclusive. Some studies have indicated that the positive association with IGF-1 is observed only for low-grade prostate cancer (Gleason sum < 7). We previously reported in the Health Professionals Follow-up Study (HPFS) a direct positive association between ELISA-measured plasma IGF-1 and IGFBP-3 and risk of prostate cancer (462 cases diagnosed after providing a blood specimen (between 1993 and 1995), but before February 1998). With additional follow-up through January 31st 2004, and 1,331 case-control pairs in total, we were now able to investigate low-grade (Gleason sum < 7, n = 635) and high-grade (Gleason sum ≥ 7, n = 515) prostate cancer separately. Matched odds ratios (OR) and 95% confidence intervals (CI) were estimated using conditional logistic regression. ORs of total prostate cancer comparing top to bottom quartiles were 1.41 (95% CI 1.12-1.78, p-trend = 0.001) for IGF-1 and 1.58 (95% CI 1.24-2.01, p-trend = 0.003) for IGFBP-3. IGF-1 was more strongly associated with low-grade (OR = 1.61 top versus bottom quartile, 95% CI 1.16-2.25, p-trend = 0.01), than with high-grade (OR = 1.29, 95% CI 0.89-1.88, p-trend = 0.12) prostate cancer (p-heterogeneity = 0.08). We hypothesize that these findings reflect that high-grade prostate cancers are more autonomous, and, thus, less sensitive to the action of IGF-1 than low-grade cancers.
Nimptsch
Katharina
K
Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA. knimptsc@hsph.harvard.edu
Platz
Elizabeth A
EA
Pollak
Michael N
MN
Kenfield
Stacey A
SA
Stampfer
Meir J
MJ
Willett
Walter C
WC
Giovannucci
Edward
E
D004797:Enzyme-Linked Immunosorbent Assay; D005500:Follow-Up Studies; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008297:Male; D009367:Neoplasm Staging; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery; D012016:Reference Values
D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I
Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1101-2
11588138
Am J Epidemiol. 2008 Mar 15;167(6):653-66
18230679
Cancer Metastasis Rev. 1998-1999;17(4):383-90
10453282
Science. 1998 Jan 23;279(5350):563-6
9438850
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2269-72
16172243
Cancer Causes Control. 2005 Apr;16(3):255-62
15947877
Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1121-7
17548673
Ann Intern Med. 2008 Oct 7;149(7):461-71, W83-8
18838726
N Engl J Med. 2003 Jul 17;349(3):215-24
12824459
Cancer Causes Control. 2003 Oct;14(8):721-6
14674736
Carcinogenesis. 2008 Dec;29(12):2335-40
18784358
Nutr Cancer. 2000;36(1):101-11
10798222
Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):48-52
15668475
Cancer. 2005 Jan 1;103(1):76-84
15540247
J Clin Oncol. 2004 Aug 1;22(15):3104-12
15284261
Curr Pharm Des. 2007;13(7):719-27
17346186
J Natl Cancer Inst. 2002 Jul 17;94(14):1099-106
12122101
J Clin Oncol. 2009 Jul 20;27(21):3459-64
19433685
Clin Nutr. 2007 Apr;26(2):252-63
17337101
Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):260-9
14973107
Cancer Res. 2003 Jul 15;63(14):3991-4
12873996
Int J Cancer. 2009 May 15;124(10):2416-29
19142965
J Cancer Res Clin Oncol. 2007 Jun;133(6):351-9
17219202
Br J Cancer. 2006 Jul 3;95(1):112-7
16804529
Int J Cancer. 2007 Nov 15;121(10):2267-73
17597108
J Natl Med Assoc. 2007 Jul;99(7):718-22
17668637
Cancer Res. 1999 Sep 1;59(17):4291-6
10485474
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1137-41
16775172
J Clin Endocrinol Metab. 2000 Nov;85(11):4258-65
11095464